Hackensack Meridian Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Hackensack Meridian Health sits in the top decile of US sponsors by registered trial count (#261 of 15,742 sponsors by registered trial count).
Hackensack Meridian Health: 90 sponsored US clinical trials, 23 recruiting.
Hackensack Meridian Health sponsors 90 registered US clinical trials on ClinicalTrials.gov, 23 of them currently recruiting, and 34 completed. 6 of these trials are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 5 trials.
Top-decile sponsor footprint
Hackensack Meridian Health ranks in the top decile of sponsors by registered trial count (#261 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
34 of 62 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (54.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
90 total, page 1 of 2
Emotional Awareness Therapy Study
NCT07624825
Clinical Trial Comparing the Efficacy of Two Teletherapy Programs at Improving Psychological Health in People With Brain Injury
NCT07436754
Ceftriaxone for Post-Treatment Lyme Disease
NCT06785402
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
NCT07214688
Predictive Value of Lung Ultrasound for Respiratory Decompensation in Late Preterm Neonates
NCT07216053
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
NCT07011342
OBWELL: Innovative Psychotherapeutic Intervention to Treat Postpartum Depression
NCT06991166
Transitions of Care Clinic (TOCC)
NCT06937827
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
NCT06798558
Leveraging the Emergency Department (LEAD) Study
NCT06605534
CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management
NCT06804395
Endometrial Cell Collection With the PadKit
NCT06464107
Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma
NCT05726383
Support for Cancer Patients Awaiting News
NCT06199570
Evaluation of the Effects of Ketorolac Dose on Duration of Analgesia in Emergency Department (ED) Renal Colic Patients
NCT05776953
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
NCT05715229
Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery
NCT05657990
Cardiac Rehabilitation of Stroke Survivors (SRP-CROSS)
NCT05651945
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
NCT05199311
ETMR One: An International Registry and Research Platform for Children With Embryonal Tumor With Multilayer Rosettes
NCT04794686
AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
NCT04263025
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
NCT03909412
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
NCT03609580
Respiratory Transition Without Continuous Positive Airway Pressure
NCT07390812
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
NCT02446236
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01297764
Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant
NCT07621796
Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration
NCT07442669
Culturally Tailored Diabetes Education on Self-Management of Adult Hispanic Males With Type 2 Diabetes Mellitus
NCT06897618
Speech-derived Digital Biomarkers Study
NCT06994767
Assessing Social Determinants of Health to Increase Cancer Screening
NCT06052449
The INSPIRE-Lung Study
NCT05824273
Prophylactic Analgesic and Antiemetic Regimen for Medical Abortion < 70 Days
NCT05819619
Continuous Glucose Monitoring and Diabetes
NCT05840250
Arrythmia Burden in Cardiac Contractility Modulation (CCM)
NCT05704426
Music Therapy Advocacy Recording Intervention (MTAR) on Internalized Stigma
NCT05723328
Quit & Fit 2.0: Feasibility and Usability Testing
NCT05878990
Fluoroquinolone Resistance Prevalence Study
NCT05824689
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
NCT04700176
Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study
NCT05096884
Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers
NCT05121766
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
NCT04456413
Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
NCT04583163
Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers
NCT04345653
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
NCT04343755
A Prospective "Universal" Observational Database for COVID-19
NCT04347993
Ketamine for Pain in the Emergency Department
NCT03896230
DECIDE: Developing Tools for Lung Cancer Screening Discussion Improvement
NCT03891602
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
NCT02846376
Parkinson's Disease Inpatient Clinical Knowledge and Management
NCT03888287
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 19 |
| Phase 3 | 4 |
| Phase 4 | 2 |
What is open in the Hackensack Meridian Health pipeline
23 recruiting of 90 indexed (26% open); 34 completed (38%).
Phase mix: 6 late (III/IV) vs 43 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Hackensack Meridian Health: open-pipeline peers nationwide
Peers matched on 90 registered trials and 26% open enrollment, not the therapeutic-area sidebar.
Hackensack Meridian Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 90 trials (± recruiting share)
- ModernaTX · 90 trials · 14% recruiting
- National Institute of Dental and Craniofacial Research (NIDCR) · 91 trials · 12% recruiting
- University of Central Florida · 91 trials · 42% recruiting
- Abbott Nutrition · 89 trials · 1% recruiting
Sponsors near 26% open enrollment (± trial volume)
- Syracuse University · 26% recruiting · 31 trials
- Shirley Ryan AbilityLab · 26% recruiting · 138 trials
- University Health Network, Toronto · 26% recruiting · 23 trials
- AB Science · 25% recruiting · 8 trials
Related
What to do with this Hackensack Meridian Health page
90 registered trials is a research-attention snapshot, not an endorsement of Hackensack Meridian Health or any single study.
- 23 of Hackensack Meridian Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition Hackensack Meridian Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Hackensack Meridian Health pipeline card: 90 registered trials from official public datasets.Report a data error.